Wugen
PrivateLast Round
Early Funding
Aug 27, 2025
Total Funding Raised
$323M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Allotera Therapeutics, Inc. is a biotechnology company developing allogeneic, off-the-shelf CAR-T cell therapies for the treatment of hematological malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Wugen Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Wugen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 27, 2025 | ||||
| Series B | Jul 15, 2021 |
Key People
Founding team and executive leadership
Wugen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LYZZ Capital | Series B, Early Funding, Series A |
| Intermediate Capital Group | Early Funding, Series B |
| Fidelity Management & Research Company | Series B, Early Funding |
| Tybourne Capital Management | Early Funding, Series B |
| RiverVest Venture Partners | Series B, Early Funding, Series A |
| Abingworth | Early Funding, Series B |
| Alexandria Venture Investments | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2025
$115M raised in early funding.
- Feb 26, 2025
Jim Faulkner appointed as interim CTO.
Wugen Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Wugen's valuation, stock price, and market status.